ГоловнаArchive of numbers2017Volume 25, issue 2 (91)Atypical antipsychotics in treatment of negative symptoms of paranoid schizophrenia
Title of the article Atypical antipsychotics in treatment of negative symptoms of paranoid schizophrenia
Authors Kozhyna  Hanna
Korostiy Volodymyr
Strelnikova Iryna
Zelenska Kateryna
In the section HELP TO PRACTICAL PHYSICIAN
Year 2017 Issue Volume 25, issue 2 (91) Pages 105-107
Type of article Scientific article Index UDK 616.895.8/.87-036.1-085.214.22 Index BBK -
Abstract The aim of the study was to conduct a comparative evaluation of the effi cacy and safety of drugs Eridone (Risperidone) and Soleron (Amisulpride). There have been a comprehensive survey 146 patients of both sexes, aged 18—60 years with a diagnosis of paranoid schizophrenia. All patients were divided into two groups: fi rst group included 73 patients taking Eridone, and the second group consisted of 73 patients taking Soleron. The study showed high eff ectiveness of Eridone and Soleron in treatment of paranoid schizophrenia with predominantly negative symptoms. These substances improve the quality of life of patients. There were no significant differences in effi cacy of Soleron and Eridone in reduction of productive symptoms. Soleron was more eff ective when the hallucinatory symptoms were presented. Soleron was more eff ective when the symptoms of cognitive defi cits were expressed. Eridone was more eff ective when the symptoms of apathy were dominated. During the course of 12 weeks of treatment with Eridone and Soleron there were no patients with negative dynamics of mental status, emotional state and cognitive functions.
Key words schizophrenia, negative symptoms, social functioning, cognitive defi cit
Access to full text version of the article pdf download
Bibliography 1. Гурович, И. Я., Папусев О. О. Дифференциация подходов к изучению нарушений социального функционирования у больных шизофренией и расстhойствами шизофренического спектра и инструментарий для его оценки // Социальная и клиническая психиатрия. 2015. Т. 25 (2). С. 9—18.
2. Долішня, Н. І. Оптимістичний погляд на проблему шизофренії // НейроNews психоневрология и нейропсихиатрия. 2009. №3 (14). С. 18—19.
3. Марута, Н. А. Проблемы раннего вмешательства в психоз: фармакологические и психосоциальные технологии // Здоров’я України. 2014. № 2 (29). С. 42—43.
4. Хаустова О. О. Використання атипових нейролептиків у практичній діяльності сімейного лікаря // НейроNews. 2016. № 8 (82). С. 36—40.
5. Хаустова Е. А., Безшейко В. Г. Атипичные антипсихотики при шизофрении: эффективность, безопасность, стратегии лечения // Там же. 2014. № 1 (56).
6. Barkhof E., Meijer C. J., de Sonneville L. M. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia — a review of the past decade // Eur. Psychiatry. 2012. Vol. 27. Р. 9—18.
7. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders / [M. F. Brunette, R. E. Drake, H. Xie et al.] // Schizophrenia Bulletin. — 2006. № 32. P. 637—643.
8. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial / [L. J. van Nimwegen, L. de Haan, N. J. van Beveren et al.] // Canadian Journal of Psychiatry. 2008. № 53 (1). P. 400—405.
9. Olvares, J. Psychiatrist’s awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa // Patient Prefer Adherence. 2013. № 7. P. 121—132.
10. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes / [D. G. Robinson, M. G. Woerner, B. Napolitano et al.] // American Journal of Psychiatry. 2006. № 163. P. 2096—2102.
11. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia / [R. E. Drake, H. Xie, G. J. McHugo et al.] // Schizophrenia Bulletin. 2000. № 26. P. 441—449.
12. Substance use in a population-based clinic sample of people with first-episode psychosis / J. H. Barnett, U. Werners, S. M. Secher et al. // Br J Psychiatry. 2007. № 190 (1). P. 515—520.